ArticleMovement disorders : official journal of the Movement Disorder Society2018
Application of the Movement Disorder Society prodromal criteria in healthy G2019S-LRRK2 carriers.
Article in Movement disorders : official journal of the Movement Disorder Society, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Analysis of α-synuclein seed amplification assay in carriers ofJournal of Parkinson's disease · 2026Article
- Detecting isolated REM sleep behavior disorder at home using a lower-back wearable sensor.NPJ digital medicine · 2026Article
- Cyclic Alternating Pattern Dynamics in Individuals at Risk for Developing Parkinson's Disease.Annals of neurology · 2025Article
- Heartbeat signature for predicting motor and non-motor involvement among nonparkinsonian LRRK2 G2019S mutation carriers.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2025Article
- Self-Reported Motor and Nonmotor Symptoms, Prodromal Parkinson's Disease Probability, and Incident Parkinson's Disease in US Farmers.Movement disorders : official journal of the Movement Disorder Society · 2025Article
- Identifying Individuals in the Prodromal Phase of Parkinson's Disease: A Prospective Cohort Study.Annals of neurology · 2025Article
- Multimodal oculomotor assessment reveals prodromal markers of Parkinson's disease in non-manifesting LRRK2 G2019S mutation carriers.NPJ Parkinson's disease · 2024Article
- A retrospective study of the MDS criteria for prodromal Parkinson's disease in the general population.NPJ Parkinson's disease · 2024Article
- Defining Parkinson's Disease: Past and Future.Journal of Parkinson's disease · 2024Review
- Modeling Parkinson's disease in LRRK2 rodents.Neuronal signaling · 2023Review
- Who is at Risk of Parkinson Disease? Refining the Preclinical Phase of GBA1 and LRRK2 Variant Carriers: a Clinical, Biochemical, and Imaging Approach.Current neurology and neuroscience reports · 2023Review
- Selected autonomic signs and symptoms as risk markers for phenoconversion and functional dependence in prodromal Parkinson's disease.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2022Article
- Longitudinal clinical and biomarker characteristics of non-manifesting LRRK2 G2019S carriers in the PPMI cohort.NPJ Parkinson's disease · 2022Article
- A Remote Longitudinal Observational Study of Individuals at Genetic Risk for Parkinson Disease: Baseline Results.Neurology. Genetics · 2022Article
- Who to Enroll in Parkinson Disease Prevention Trials? The Case for Genetically At-Risk Cohorts.Neurology · 2022Review
- Evaluation of the PREDIGT score's performance in identifying newly diagnosed Parkinson's patients without motor examination.NPJ Parkinson's disease · 2022Article
- Aberrant dopamine transporter and functional connectivity patterns in LRRK2 and GBA mutation carriers.NPJ Parkinson's disease · 2022Article
- Prodromal Parkinson's disease: hype or hope for disease-modification trials?Translational neurodegeneration · 2022Review
- Prodromal Cognitive Deficits and the Risk of Subsequent Parkinson's Disease.Brain sciences · 2022Review
- A multiplex pedigree with pathologically confirmed multiple system atrophy and Parkinson's disease with dementia.Brain communications · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
backgroundIn 2015, the International Parkinson and Movement Disorder Society Task Force recommended research criteria for the estimation of prodromal PD.
objectivesWe aimed to evaluate, for the first time, the criteria in first-degree relatives of Ashkenazi Jewish G2019S-LRRK2 PD patients, who are considered a population at risk for developing PD, and assess the sensitivity and specificity of the criteria in identifying phenoconverters.
methodsParticipants were evaluated longitudinally over a period of 5 years (average follow-up: 49.2 ± 12.3 months). Likelihood ratios and probability estimations were calculated based on the International Parkinson and Movement Disorder Society Research Criteria for Prodromal Parkinson's Disease markers and examined for each assessment point.
resultsOne hundred twenty healthy carriers (49.53 ± 13.4 years; 54% female) and 111 healthy noncarriers (48.43 ± 15.79 years; 49% female) participated in this study. Probability scores were significantly higher in healthy carriers than healthy noncarriers (P < 0.0001). Of the 20 participants (8.6%) who met criteria for probable prodromal PD at baseline, 17 were healthy carriers. Participants who reached the threshold were older (P < 0.0001), had higher UPDRS-III (P < 0.001), lower cognitive function (P = 0.001), and more nonmotor symptoms (P < 0.0001), compared to those who did not. Ten participants were diagnosed with incident PD within 5 years from baseline resulting in a specificity of 91.82% (95% confidence interval: 86.69-96.94), sensitivity of 80% (95% confidence interval: 55.21-100), positive predictive value of 47.06% (95% confidence interval: 23.33-70.79), and negative predictive value of 98.06% (95% confidence interval: 95.39-100). All 10 phenoconvertors were G2019S-LRRK2 carriers.
conclusionsThe results showed the utility of using the criteria and high sensitivity and specificity in identifying prodromal PD in this high-risk unique cohort. These results may be valuable for future disease modification clinical trials. © 2018 International Parkinson and Movement Disorder Society.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.